The participants under study are recruited from a sample of patients suffering from a severe form of the Gilles-de-la-Tourette-syndrome who are waiting to receive deep-brain stimulation of the ncl. accumbens as therapeutic treatment.
Conditions
Interventions
Product Name: [18F] Fallypride
Pharmaceutical Form: Injection*
INN or Proposed INN: [18F]Fallypride
Concentration unit: MBq/ml megabecquerel(s)/millilitre
Concentration type: range
Concentration numbe
Sponsors
University of Aachen
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. only patients will be included who hav acceded to undergo deep brain stimulation for treatment of their Tourette-syndrome; 2. as a consequence of 1. patients will -be over 18 years of age -have a certain diagnosis of GTS -have a severe, chronic and medically refractory form of GTS Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1. existence of other physical or neurological indispositions that might interfere with the study parameters or provide a risk to the patient in the course of the study 2. pregnancy 3. propofol hypersensitivity 4. incapability of giving consent personally
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Monitoring effects of deep brain stimulation of the ncl. accumbens on the dopamine transmission in patients with Gilles-de-la-tourette.;Secondary Objective: To study the correlation between dopamine transmission and symptome severity.;Primary end point(s): Dopamine transmission as quantified by [18F]Fallypride-PET | — |
Countries
Germany
Outcome results
None listed